Case Report: Ivarmacitinib in the treatment of refractory primary cutaneous amyloidosis - Scorecard - MDSpire

Case Report: Ivarmacitinib in the treatment of refractory primary cutaneous amyloidosis

  • By

  • Xiaofan Liao

  • Xian Huang

  • Guilan Yang

  • Xia Wang

  • Qifeng Li

  • Yuan Lu

  • May 8, 2026

  • 0 min

Share

Clinical Scorecard: Clinical Case Study: Efficacy of Ivarmacitinib for Refractory Primary Cutaneous Amyloidosis

At a Glance

CategoryDetail
Condition
Key MechanismsAccumulation of amyloid in the dermal layer, dysregulated immune responses involving Th2 cytokines and JAK/STAT pathway.
Target Population
Care Setting

Key Highlights

  • highlight_5

Guideline-Based Recommendations

Diagnosis

    Management

    • Consider ivarmacitinib for patients with refractory PCA.
    • Explore combination therapies or adjunctive treatments.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Ivarmacitinib was administered at 4 mg orally once daily for 8 weeks with follow-up assessments.

        Clinical Best Practices

        • best_practice_1

        Related Resources & Content

        Original Source(s)

        Case Report: Ivarmacitinib in the treatment of refractory primary cutaneous amyloidosis

        • by Xiaofan Liao, Xian Huang, Guilan Yang, Xia Wang, Qifeng Li, Yuan Lu

        • May 8, 2026

        Related Content

        Evaluating Itch in Atopic Dermatitis: Perspectives from UK Dermatologists Through a Cross-Sectional Survey and Narrative Review

        Analysis of Health Claims Data for German Patients with Atopic Dermatitis Not Adequately Managed by Standard Systemic Treatments

        Extracellular vesicles in atopic dermatitis: unraveling pathogenic mediators and engineering therapeutic vectors